Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Bone Biologics Corp (BBLG)

Bone Biologics Corp (BBLG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities GlobeNewswire - Thu Jul 23, 7:00AM CDT

BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets,...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire - Tue Jul 7, 7:00PM CDT

BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics,” or the “Company”), a developer of orthobiologic products for spine fusion...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1 GlobeNewswire - Tue May 19, 7:00AM CDT

BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets,...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook GlobeNewswire - Thu Jan 8, 7:00AM CST

BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets,...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months GlobeNewswire - Tue Dec 23, 2025

BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets,...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook Business Wire - Thu Sep 4, 2025

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference Business Wire - Wed Sep 3, 2025

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President...

BBLG : 1.1100 (+2.78%)
BBLGW : 9.53 (-3.74%)
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia Business Wire - Tue Apr 11, 2023

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first...

BBLG : 1.1100 (+2.78%)
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization Business Wire - Thu Jan 26, 2023

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s...

BBLG : 1.1100 (+2.78%)
Bone Biologics CEO Issues Letter to Stockholders Business Wire - Tue Oct 25, 2022

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer,...

BBLG : 1.1100 (+2.78%)

Barchart Exclusives

As Musk Teases Tesla-SpaceX Merger, Here's What Shareholders Should Expect Barchart - 20 minutes ago
Predictions of a merger between the two are going higher by the day. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.